Ipamorelin 5mg

KEY BENEFITS

• Selectively stimulates growth hormone (GH) release without significantly increasing cortisol or prolactin in research settings

• Highly targeted activity at the ghrelin (GHS-R1a) receptor compared to earlier growth hormone secretagogues

• Short-acting and predictable signaling profile, making it popular in controlled research protocols

• Commonly studied for its cleaner side-effect profile versus older GH-releasing compounds

Full Description

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue (GHS). It is designed to bind specifically to the growth hormone secretagogue receptor (GHS-R1a), triggering a signaling cascade in the pituitary that promotes endogenous growth hormone release.

Unlike earlier GHS compounds, ipamorelin demonstrates high receptor selectivity, which is why it is widely studied for its ability to stimulate growth hormone secretion with minimal off-target endocrine activity. In laboratory and preclinical research, ipamorelin has shown little to no meaningful stimulation of cortisol or prolactin release, making it a preferred research compound when a more focused GH-pathway response is desired.

Because ipamorelin works by signaling the body’s own growth hormone release rather than introducing exogenous hormone, it is commonly investigated in models exploring physiological recovery, metabolic signaling, and tissue remodeling pathways.

This product is supplied strictly for laboratory and research use only.

Commonly Explored For (Research Use Only)

• Growth hormone signaling and pulsatility models

• Recovery and tissue repair pathways

• Body composition and metabolic signaling research

• Musculoskeletal recovery and regeneration studies

• Sleep and circadian-related GH release investigations